1. Mast Cells in Inflammation {#sec1-ijms-20-03701}
=============================

Mast cells derive from bone marrow progenitors and mature perivascularly in all tissues \[[@B1-ijms-20-03701]\], where they are involved in allergic reactions \[[@B2-ijms-20-03701]\]. Mast cells also act as sensors of environmental stress \[[@B3-ijms-20-03701]\].

In addition to allergens, mast cells are also stimulated by pathogens \[[@B4-ijms-20-03701]\], drugs, foods, heavy metals, and "danger signals" \[[@B2-ijms-20-03701]\], as well as certain neuropeptides including corticotropin-releasing hormone (CRH) \[[@B5-ijms-20-03701]\], neurotensin (NT) \[[@B6-ijms-20-03701]\] and substance P (SP) \[[@B7-ijms-20-03701],[@B8-ijms-20-03701]\]. Both NT \[[@B9-ijms-20-03701],[@B10-ijms-20-03701]\] and SP \[[@B11-ijms-20-03701],[@B12-ijms-20-03701],[@B13-ijms-20-03701],[@B14-ijms-20-03701]\] are known to participate in inflammatory processes. Stimulated mast cells can secrete numerous bioactive mediators \[[@B15-ijms-20-03701],[@B16-ijms-20-03701],[@B17-ijms-20-03701]\], utilizing different secretory pathways \[[@B18-ijms-20-03701]\]. Some of these mediators are prestored in secretory granules such as histamine, tryptase and tumor necrosis factor (TNF) \[[@B19-ijms-20-03701],[@B20-ijms-20-03701]\]; others are synthesized de novo and include leukotrienes, prostaglandins, chemokines (CCXL8, CCL2) and cytokines \[[@B20-ijms-20-03701],[@B21-ijms-20-03701]\], that include pro- and anti-inflammatory members, \[[@B22-ijms-20-03701]\]. Many mediators can be secreted from mast cells selectively without degranulation \[[@B23-ijms-20-03701]\]. In particular, CRH stimulates cultured human mast cells to produce vascular endothelial growth factor (VEGF) without tryptase \[[@B5-ijms-20-03701]\].

As a result, mast cells are not only critical for allergic reactions \[[@B2-ijms-20-03701],[@B24-ijms-20-03701]\], but are also important in innate and acquired immunity \[[@B25-ijms-20-03701],[@B26-ijms-20-03701]\], antigen presentation \[[@B27-ijms-20-03701],[@B28-ijms-20-03701]\] and inflammation \[[@B29-ijms-20-03701],[@B30-ijms-20-03701]\].

2. IL-37 as An Anti-Inflammatory Agent {#sec2-ijms-20-03701}
======================================

The IL-1 family comprises of IL-1a, IL-1b, IL-18, IL-33, IL-36a, IL-36b, IL-36g, IL-37, and IL-38 \[[@B31-ijms-20-03701]\]. Interleukin-37 (IL-37, formerly IL-1F7) belongs to the IL-1 family of cytokines \[[@B7-ijms-20-03701],[@B32-ijms-20-03701],[@B33-ijms-20-03701]\] and is a natural suppressor of immunity and inflammation \[[@B21-ijms-20-03701],[@B34-ijms-20-03701],[@B35-ijms-20-03701]\].

Five isoforms (a--e) have so far been identified \[[@B34-ijms-20-03701]\]. The "b" isoform of IL-37 used here is the most commonly used, but the d isoform was also reported to inhibit the expression of pro-inflammatory cytokines in PBMCs \[[@B36-ijms-20-03701]\]. A specific receptor has not yet been identified for IL-37. A number of studies reported that extracellular IL-37 binds to the alpha chain of the IL-18 receptor (IL-18Rα) \[[@B37-ijms-20-03701],[@B38-ijms-20-03701]\], but with much lower binding affinity than that of IL-18 \[[@B39-ijms-20-03701]\].

Both the precursor and mature IL-37 bind IL-18Rα \[[@B39-ijms-20-03701]\]. In addition, IL-37 binds to an IL-18 binding protein (IL-18BP) \[[@B40-ijms-20-03701]\], and to the decoy receptor 8 (IL-R8) \[[@B41-ijms-20-03701]\] via which extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo \[[@B42-ijms-20-03701]\]. Extracellularly, the IL-37 monomer is the active form involved in reducing innate immunity \[[@B43-ijms-20-03701]\]; instead, homodimerization of IL-37 reduces its anti-inflammatory activity \[[@B44-ijms-20-03701]\]. The precise inhibitory mechanism of action of IL-37 is presently not known. One possibility may be that it inhibits mammalian target of rapamycin (mTOR) \[[@B45-ijms-20-03701]\] since this complex was reported to be involved in the stimulatory action of NT on human microglia \[[@B46-ijms-20-03701]\]. Another possibility may be that IL-37 inhibits inflammasome activation as reported in murine aspergillosis \[[@B47-ijms-20-03701]\].

There have been apparently contradicting findings of increased IL-37 in inflammatory states reported in the literature. For instance, IL-37 was reported to be increased in the brain and plasma of patients after ischemic stroke and protected them from inflammatory brain injury \[[@B48-ijms-20-03701]\]. Other studies also showed elevated serum IL-37 concentration in patients with sepsis \[[@B49-ijms-20-03701]\] and in ankylosing spondylitis \[[@B50-ijms-20-03701]\]. Instead, a state of IL-37 deficiency has been reported in calcific aortic stenosis \[[@B51-ijms-20-03701]\].

Increased gene expression of IL-37 was associated with suppression of IL-1β and IL-6 production from peripheral blood mononuclear cells (PBMCs) from subjects with systemic inflammatory diseases \[[@B22-ijms-20-03701],[@B50-ijms-20-03701],[@B52-ijms-20-03701],[@B53-ijms-20-03701],[@B54-ijms-20-03701],[@B55-ijms-20-03701]\]. IL-37 has been reported to inhibit the generation of pro-inflammatory cytokines in vitro \[[@B56-ijms-20-03701]\], as well as in vivo \[[@B57-ijms-20-03701]\], but apparently require the IL-1 family decoy receptor IL-1R8 \[[@B58-ijms-20-03701]\].

3. Mast Cell-Derived Heparin and Tryptase May Regulate IL-37 {#sec3-ijms-20-03701}
============================================================

IL-37 is made primarily by macrophages in response to toll-like receptor (TLR) activation, following which, an IL-37 precursor (pro-IL-37) is cleaved by caspase-1 into mature IL-37. Some of this IL-37 enters the nucleus while the rest is released along with pro-IL-37 outside the cells \[[@B59-ijms-20-03701]\] where both are biologically active. It was recently reported that extracellular IL-37 is active as the monomer, while binding to heparin promotes its homodimerization, with the IL-37 dimers blocking the activity of the IL-37 monomer \[[@B43-ijms-20-03701]\]. Extracellular proteases, hypothesized to be secreted by macrophages, can process pro-IL-37 into a much more biologically active form as shown for recombinant IL-37b with the N-terminus Val46 (V46-218) \[[@B60-ijms-20-03701]\].

Mast cells are the richest source of heparin \[[@B61-ijms-20-03701]\] and the only source of tryptase \[[@B62-ijms-20-03701]\] in the body. Mast cells could regulate the anti-inflammatory activity of IL-37 in different ways ([Figure 1](#ijms-20-03701-f001){ref-type="fig"}). Heparin will inhibit the action of IL-37 by promoting the creation of homodimers \[[@B43-ijms-20-03701]\]. Moreover, heparin would stabilize the tryptase homotetramer that would promote inflammation via activation of protease-activated receptors (PAR) \[[@B63-ijms-20-03701]\]. Instead, tryptase monomers could generate mature, superactive IL-37 \[[@B60-ijms-20-03701]\], in a method analogous to what had been reported for IL-33 \[[@B64-ijms-20-03701],[@B65-ijms-20-03701]\].

4. Conclusions {#sec4-ijms-20-03701}
==============

We believe that the ratio of IL-1 to IL-37 is a determining factor in inflammatory diseases. Several drugs targeting IL-1β or its soluble IL-1R are available for treating inflammatory conditions \[[@B66-ijms-20-03701]\], but there is still a need for more effective management of inflammation. IL-37 would be superior to other biologics beacause it is capable of inhibiting the generation of both cytokines and chemokines. IL-37 may also be administered together with other natural molecules \[[@B67-ijms-20-03701],[@B68-ijms-20-03701]\], such as the flavonoid tetramethoxyluteolin, which has been reported to inhibit mast cell release of cytokines \[[@B8-ijms-20-03701],[@B69-ijms-20-03701]\].
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![Diagrammatic representation of the role of mast cell-derived heparin in the regulation of the activity of IL-37. Activation of caspase 1 in macrophages, in response to TLR activation, leads to cleavage of pro-IL-37 to mature IL-37, both of which are secreted outside the cell and have anti-inflammatory activity. In the tissue microenvironment, mast cells secrete heparin, which interacts with IL-37 and promotes the formation of inactive homodimers. Mast cells also secrete the proteolytic enzyme tryptase, which exists as homotetramer bound to heparin and promotes inflammation by acting on protease-activated receptors (PAR). In the absence of heparin, biologically active tryptase monomers may be able to generate IL-37 forms with increased anti-inflammatory activity. Open arrows = activation; thin arrows = secretion; thick arrows = stimulation; T arrows = inhibition.](ijms-20-03701-g001){#ijms-20-03701-f001}
